Genetics and epigenetics purpose in nonalcoholic fatty liver disease

References

• Salva-Pastor N, Chávez-Tapia NC, Uribe M, et al. The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider. Gastroenterol Hepatol Bed Bench. 2019;12:267–277.
   PubMedGoogle Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int. 2016;36:1563–1579.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States From 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.
   PubMed Web of Science ®Google Scholar
• Kim H, Worsley O, Yang E, et al. Persistent changes in liver methylation and microbiome composition following reversal of diet-induced non-alcoholic-fatty liver disease. Cell Mol Life Sci. 2019;76(21):4341-4354.
   Web of Science ®Google Scholar
• Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int J Mol Sci. 2015;16:5161–5179.
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038–1048.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim Y, Friso S, et al. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2017;54:78–88.
   PubMed Web of Science ®Google Scholar
• Zhao F. Dysregulated epigenetic modifications in the pathogenesis of NAFLD-HCC. Adv Exp Med Biol. 2018;1061:79–93.
   PubMed Web of Science ®Google Scholar
• Wei JL, Leung JCF, Loong TCW, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110:1306–1314.
   PubMed Web of Science ®Google Scholar
• Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017;15:1604–1611.e1.
   PubMed Web of Science ®Google Scholar
• Del Campo JA, Gallego-Durán R, Gallego P, et al. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J Mol Sci. 2018;19:5–10.
   Web of Science ®Google Scholar
• Valenti L, Motta BM, Alisi A, et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2012;54:588–593.
   PubMed Web of Science ®Google Scholar
• Reue K, Zhang P. The lipin protein family: dual roles in lipid biosynthesis and gene expression. FEBS Lett. 2008;582:90–96.
   PubMed Web of Science ®Google Scholar
• Berardi MJ, Chou JJ. Fatty acid flippase activity of UCP2 is essential for its proton transport in mitochondria. Cell Metab. 2014;20:541–552.
   PubMed Web of Science ®Google Scholar
• Fares R, Petta S, Lombardi R, et al. The UCP2-866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int. 2015;35:1574–1580.
   PubMed Web of Science ®Google Scholar
• Miele L, Beale G, Patman G, et al. The kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology. 2008;135:282–291.
   PubMed Web of Science ®Google Scholar
• Al-Serri A, Anstee QM, Valenti L, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol. 2012;56:448–454.
   PubMed Web of Science ®Google Scholar
• Eslam M, Hashem AM, Leung R, et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun. 2015;6:1–10.
   Web of Science ®Google Scholar
• Petta S, Valenti L, Svegliati-Baroni G, et al. Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2017;102:2660–2669.
   PubMed Web of Science ®Google Scholar
• Metwally M, Bayoumi A, Romero-Gomez M, et al. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR. J Hepatol. 2019;70:494–500.
   PubMed Web of Science ®Google Scholar
• Hsiao TJ, Lin E. The ENPP1 K121Q polymorphism is associated with type 2 diabetes and related metabolic phenotypes in a Taiwanese population. Mol Cell Endocrinol. 2016;433:20–25.
   PubMed Web of Science ®Google Scholar
• Kommoju UJ, Maruda J, Kadarkarai Samy S, et al. Association of IRS1, CAPN10, and PPARG gene polymorphisms with type 2 diabetes mellitus in the high-risk population of Hyderabad, India. J Diabetes. 2014;6:564–573.
   PubMed Web of Science ®Google Scholar
• Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011; 7.
   PubMed Web of Science ®Google Scholar
• Gorden A, Yang R, Yerges-Armstrong LM, et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum Hered. 2013;75:34–43.
   PubMed Web of Science ®Google Scholar
• Pelusi S, Baselli G, Pietrelli A, et al. Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease. Sci Rep. 2019;9:1-10.
   Web of Science ®Google Scholar
• Hyysalo J, Stojkovic I, Kotronen A, et al. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2012;27:951–956.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–1894.
   PubMed Web of Science ®Google Scholar
• Xu M, Li Y, Zhang S, et al. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China. Ann Hepatol. 2019;18:456–460.
   PubMed Web of Science ®Google Scholar
• Boonvisut S, Yoshida K, Nakayama K, et al. Identification of deleterious rare variants in MTTP, PNPLA3, and TM6SF2 in Japanese males and association studies with NAFLD. Lipids Health Dis. 2017;16:1–9.
   PubMed Web of Science ®Google Scholar
• Mazo DF, Malta FM, Stefano JT, et al. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Ann Hepatol. 2019;18:466–471.
   PubMed Web of Science ®Google Scholar
• BasuRay S, Wang Y, Smagris E, et al. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A. 2019;116:9521–9526.
   PubMed Web of Science ®Google Scholar
• Feldman A, Eder SK, Felder TK, et al. Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol. 2017;112:102–110.
   PubMed Web of Science ®Google Scholar
• Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010;107:7892–7897.
   PubMed Web of Science ®Google Scholar
• Pirazzi C, Valenti L, Motta BM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014;23:4077–4085.
   PubMed Web of Science ®Google Scholar
• Bruschi FV, Claudel T, Tardelli M, et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 2017;65:1875–1890.
   PubMed Web of Science ®Google Scholar
• He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706–6715.
   PubMed Web of Science ®Google Scholar
• Pirazzi C, Adiels M, Burza MA, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012;57:1276–1282.
   PubMed Web of Science ®Google Scholar
• Brouwers MCGJ, Simons N, Stehouwer CDA, et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia. 2019;11:253–260. Springer.
   Google Scholar
• Abul-Husn NS, Cheng X, Li AH, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378:1096–1106.
   PubMed Web of Science ®Google Scholar
• BasuRay S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte. 2019;8:201–208.
   PubMed Web of Science ®Google Scholar
• Lindén D, Ahnmark A, Pingitore P, et al. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab. 2019;22:49–61.
   PubMed Web of Science ®Google Scholar
• Kovarova M, Königsrainer I, Königsrainer A, et al. The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl-palmitate storage in humans. J Clin Endocrinol Metab. 2015;100:E1568–E1574.
   PubMed Web of Science ®Google Scholar
• Kumashiro N, Yoshimura T, Cantley JL, et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology. 2013;57:1763–1772.
   PubMed Web of Science ®Google Scholar
• Carim-Todd L, Escarceller M, Estivill X, et al. Cloning of the novel gene TM6SF1 reveals conservation of clusters of paralogous genes between human chromosomes 15q24→q26 and 19p13.3→p12.. Cytogenet Cell Genet. 2000;90:255–260.
   PubMedGoogle Scholar
• Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A. 2014;111:8913–8918.
   PubMed Web of Science ®Google Scholar
• Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352–356.
   PubMed Web of Science ®Google Scholar
• Mancina RM, Sentinelli F, Incani M, et al. Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children. Dig Liver Dis. 2016;48:100–101.
   PubMedGoogle Scholar
• Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. 2014
   Google Scholar
• Fan Y, Lu H, Guo Y, et al. Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice. Gastroenterology. 2016;150:1208–1218.
   PubMed Web of Science ®Google Scholar
• Smagris E, Gilyard S, BasuRay S, et al. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem. 2016;291:10659–10676.
   PubMed Web of Science ®Google Scholar
• Prill S, Caddeo A, Baselli G, et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Sci Rep. 2019;9:1–12.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Yamamori N, Kono N, et al. Identification of small subunit of serine palmitoyltransferase a as a lysophosphatidylinositol acyltransferase 1-interacting protein. Genes Cells. 2013;18:397–409.
   PubMed Web of Science ®Google Scholar
• Zarini S, Hankin JA, Murphy RC, et al. Lysophospholipid acyltransferases and eicosanoid biosynthesis in zebrafish myeloid cells. Prostaglandins Other Lipid Mediat. 2014;113–115:52–61.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Shimanaka Y, Caddeo A, et al. LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. Gut. 2020.
   Google Scholar
• Helsley RN, Varadharajan V, Brown AL, et al. Obesity-linked suppression of membrane-bound o-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. Elife. 2019;8:1–69.
   Web of Science ®Google Scholar
• Wu Q, Ortegon AM, Tsang B, et al. FATP1 is an insulin-sensitive fatty acid transporter involved in diet-induced obesity. Mol Cell Biol. 2006;26:3455–3467.
   PubMed Web of Science ®Google Scholar
• Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent. Gastroenterology. 2016;150:1219–1230.e6.
   PubMed Web of Science ®Google Scholar
• Donati B, Dongiovanni P, Romeo S, et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. 2017;7.
   Web of Science ®Google Scholar
• Meroni M, Dongiovanni P, Longo M, et al. Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes: mboat7 reduction and hepatic steatosis. EBioMedicine. 2020;52.
   PubMed Web of Science ®Google Scholar
• Peter A, Stefan N, Cegan A, et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab. 2011;96(7):E1126-E1130.
   Web of Science ®Google Scholar
• Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 2009;66(1):27–42.
   PubMed Web of Science ®Google Scholar
• Simons PIHG, Simons N, Stehouwer CDA, et al. Association of common gene variants in glucokinase regulatory protein with cardiorenal disease: A systematic review and meta-analysis. PLoS One. 2018;13.
   Web of Science ®Google Scholar
• Kumar A, Shalimar WGK, Gupta V, et al. Genetics of nonalcoholic fatty liver disease in Asian populations. J Genet Springer. 2019;98(1):29.
   Web of Science ®Google Scholar
• Tan HL, Zain SM, Mohamed R, et al. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J Gastroenterol. 2014;49:1056–1064.
   PubMed Web of Science ®Google Scholar
• Vilar CP, Cotrim HP, Florentino GSA, et al. Doença hepática gordurosa não alcoólica em pacientes com doença coronariana de uma área do nordeste do Brazil. Arq Gastroenterol. 2015;52:111–116.
   PubMedGoogle Scholar
• Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. 2009;18:4081–4088.
   PubMed Web of Science ®Google Scholar
• Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;55:781–789.
   PubMed Web of Science ®Google Scholar
• Sliz E, Sebert S, Würtz P, et al. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects. Hum Mol Genet. 2018;27(12):2214–2223.
   PubMed Web of Science ®Google Scholar
• Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865–872.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Orešič M, Leivonen M, et al. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites. Clin Gastroenterol Hepatol. 2016;14:1463–1472.e6.
   PubMed Web of Science ®Google Scholar
• Nobili V, Donati B, Panera N, et al. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2014;58:632–636.
   PubMed Web of Science ®Google Scholar
• Krawczyk M, Jiménez-Agüero R, Alustiza JM, et al. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis. 2016;12:1838–1846.
   PubMed Web of Science ®Google Scholar
• Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–1068.
   PubMed Web of Science ®Google Scholar
• Stols-Gonçalves D, Tristão LS, Henneman P, et al. Epigenetic markers and microbiota/metabolite-induced epigenetic modifications in the pathogenesis of obesity, metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease. Curr Diab Rep. 2019;19:1–9.
   PubMed Web of Science ®Google Scholar
• van der Wijst MGP, Venkiteswaran M, Chen H, et al. Local chromatin microenvironment determines DNMT activity: from DNA methyltransferase to DNA demethylase or DNA dehydroxymethylase. Epigenetics. 2015;10:671–676.
   PubMed Web of Science ®Google Scholar
• Tryndyak VP, Han T, Muskhelishvili L, et al. Coupling global methylation and gene expression profiles reveal key pathophysiological events in liver injury induced by a methyl-deficient diet. Mol Nutr Food Res. 2011;55:411–418.
   PubMed Web of Science ®Google Scholar
• Law JA, Jacobsen SE. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat Rev Genet. 2010;11:204–220.
   PubMed Web of Science ®Google Scholar
• Wu Y, Bu F, Yu H, et al. Methylation of Septin9 mediated by DNMT3a enhances hepatic stellate cells activation and liver fibrogenesis. Toxicol Appl Pharmacol. 2017;315:35–49.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Fernández Gianotti T, Burgueño AL, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. 2013;62:1356–1363.
   PubMed Web of Science ®Google Scholar
• Park LK, Friso S, Choi SW. Nutritional influences on epigenetics and age-related disease. Proc Nutr Soc. 2012;71:75–83.
   PubMed Web of Science ®Google Scholar
• Tibbetts AS, Appling DR. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr. 2010;30:57–81.
   PubMed Web of Science ®Google Scholar
• Zeybel M, Hardy T, Robinson SM, et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Clin Epigenet. 2015;7:1–11.
   PubMed Web of Science ®Google Scholar
• Benton MC, Johnstone A, Eccles D, et al. An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome Biol. 2015;16:1–21.
   PubMed Web of Science ®Google Scholar
• Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300–1303.
   PubMed Web of Science ®Google Scholar
• Mariño-Ramírez L, Kann MG, Shoemaker BA, et al. Histone structure and nucleosome stability. Expert Rev Proteomics. 2005;2:719–729.
   PubMed Web of Science ®Google Scholar
• Huertas D, Sendra R, Muñoz P. Chromatin dynamics coupled to DNA repair. Epigenetics. 2009;4:31–42.
   PubMed Web of Science ®Google Scholar
• Luco RF, Pan Q, Tominaga K, et al. Supporting online material for regulation of alternative splicing by histone modifications. Science. 2010;327(5968):996–1001.
   PubMed Web of Science ®Google Scholar
• Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21:381–395.
   PubMed Web of Science ®Google Scholar
• Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell. 2007;128:707–719.
   PubMed Web of Science ®Google Scholar
• Karlić R, Chung HR, Lasserre J, et al. Histone modification levels are predictive for gene expression. Proc Natl Acad Sci U S A. 2010;107:2926–2931.
   PubMed Web of Science ®Google Scholar
• Tamaru H. Confining euchromatin/heterochromatin territory: jumonji crosses the line. Genes Dev. 2010;24:1465–1478.
   PubMed Web of Science ®Google Scholar
• Riancho J, Del Real A, Riancho JA. How to interpret epigenetic association studies: a guide for clinicians. Bonekey Rep. 2016;5.
   PubMedGoogle Scholar
• Ling C, Groop L. Epigenetics: A molecular link between environmental factors and type 2 diabetes. Diabetes. 2009;58:2718–2725.
   PubMed Web of Science ®Google Scholar
• Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients. 2014;6:3303–3325.
   PubMed Web of Science ®Google Scholar
• Chan HM, La Thangue NB. p300/CBP proteins: hATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114:2363–2373.
   PubMed Web of Science ®Google Scholar
• Tian Y, Wong VWS, Chan HLY, et al. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471–482.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu Z, Li D, et al. Nutrition, epigenetics, and metabolic syndrome. Antioxid Redox Signal. 2012;17:282–301.
   PubMed Web of Science ®Google Scholar
• Feng D, Liu T, Sun Z, et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science. 2011;331:1315–1319.
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Knutson SK, Jiang G, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 2010;18:436–447.
   PubMed Web of Science ®Google Scholar
• Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008;7:104–112.
   PubMed Web of Science ®Google Scholar
• Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer. 2010;10:819–823.
   PubMed Web of Science ®Google Scholar
• Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9:327–338.
   PubMed Web of Science ®Google Scholar
• Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–874.
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KKH, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
   PubMed Web of Science ®Google Scholar
• Bartel DP. Review MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;2:281–297.
   Google Scholar
• Salvoza NC, Klinzing DC, Gopez-Cervantes J, et al. Association of circulating serum MIR-34a and MIR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease. PLoS One. 2016;11:1–12.
   Web of Science ®Google Scholar
• Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57:840–847.
   PubMed Web of Science ®Google Scholar
• Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132:4653–4662.
   PubMed Web of Science ®Google Scholar
• Panera N, Gnani D, Crudele A, et al. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15079–15086.
   PubMed Web of Science ®Google Scholar
• Vienberg S, Geiger J, Madsen S, et al. MicroRNAs in metabolism. Acta Physiol. 2017;219:346–361.
   PubMed Web of Science ®Google Scholar
• Liu X-L, Cao H-X, Wang B-C, et al. miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. World J Gastroenterol. 2017;23:8140–8151.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Gianotti TF, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800–812.
   PubMed Web of Science ®Google Scholar
• Liu X-L, Pan Q, Zhang R-N, et al. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol. 2016;22:9844.
   PubMed Web of Science ®Google Scholar
• Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol. 2015;7:226–234.
   PubMed Web of Science ®Google Scholar
• He Z, Hu C, Jia W. miRNAs in non-alcoholic fatty liver disease. Front Med. 2016;10:389–396.
   PubMed Web of Science ®Google Scholar
• Tan Y, Ge G, Pan T, et al. A pilot study of serum micrornas panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One. 2014;9:1–12.
   Web of Science ®Google Scholar
• Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3:87–98.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Sharapova T, Lake AD, et al. Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. J Appl Toxicol. 2014;34:726–732.
   PubMed Web of Science ®Google Scholar
• Yamada H, Suzuki K, Ichino N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99–103.
   PubMed Web of Science ®Google Scholar
• Hsu S, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122:2871–2883.
   PubMed Web of Science ®Google Scholar
• Csak T, Bala S, Lippai D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015;35:532–541.
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404–407.
   PubMed Web of Science ®Google Scholar
• Li ZJ, Ou-Yang PH, Han XP. Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal. 2014;26:141–148.
   PubMed Web of Science ®Google Scholar
• Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014. Hindawi Publishing Corporation.
   PubMed Web of Science ®Google Scholar
• Castro RE, Ferreira DMS, Afonso MB, et al. MiR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;58:119–125.
   PubMed Web of Science ®Google Scholar
• Ding J, Li M, Wan X, et al. Effect of MIR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. Sci Rep. 2015;5:1–10.
   Web of Science ®Google Scholar
• Derdak Z, Villegas KA, Harb R, et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol. 2013;58:785–791.
   PubMed Web of Science ®Google Scholar
• Shan W, Gao L, Zeng W, et al. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of MIR-34a protects rats against nonalcoholic fatty liver disease. Cell Death Dis. 2015;6:1–9.
   Web of Science ®Google Scholar
• Xu Y, Zalzala M, Xu J, et al. A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nat Commun. 2015;6.
   Web of Science ®Google Scholar
• Shan W, Gao L, Zeng W, et al. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of MIR-34a protects rats against nonalcoholic fatty liver disease. Cell Death Dis. 2015;6.
   PubMed Web of Science ®Google Scholar
• Sun C, Huang F, Liu X, et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med. 2015;35:847–853.
   PubMed Web of Science ®Google Scholar
• Loyer X, Paradis V, Hénique C, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut. 2016;65:1882–1894.
   PubMed Web of Science ®Google Scholar
• Rodrigues PM, Afonso MB, Simaõ AL, et al. MiR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis. 2017;8:e2748.
   Web of Science ®Google Scholar
• Vinciguerra M, Sgroi A, Veyrat-Durebex C, et al. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog(PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology. 2009;49:1176–1184.
   PubMed Web of Science ®Google Scholar
• Dattaroy D, Pourhoseini S, Das S, et al. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2015;308:G298–G312.
   PubMed Web of Science ®Google Scholar
• Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut. 2016;65:1850–1860.
   PubMed Web of Science ®Google Scholar
• Coll M, El TA, Perea L, et al. Integrative miRNA and gene expression profiling analysis of human quiescent hepatic stellate cells. Sci Rep. 2015;5:1–14.
   Web of Science ®Google Scholar
• Becker PP, Rau M, Schmitt J, et al. Performance of serum microRNAs-122,-192 and-21 as biomarkers in patients with non-Alcoholic steatohepatitis. PLoS One. 2015;10:1–16.
   Web of Science ®Google Scholar
• Lei L, Zhou C, Yang X, et al. Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 2018;45:819–831.
   PubMed Web of Science ®Google Scholar
• Liu AM, Poon RTP, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394:623–627.
   PubMed Web of Science ®Google Scholar
• He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–3369.
   PubMed Web of Science ®Google Scholar
• Godlewski J, Nowicki MO, Bronisz A, et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010;37:620–632.
   PubMed Web of Science ®Google Scholar
• Hur W, Lee JH, Kim SW, et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Int J Biochem Cell Biol. 2015;64:265–276.
   PubMed Web of Science ®Google Scholar
• Murata K, Yoshitomi H, Furu M, et al. Microrna-451 down-regulates neutrophil chemotaxis via p38 mapk. Arthritis Rheumatol. 2014;66:549–559.
   PubMed Web of Science ®Google Scholar
• Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103(2):71–83.
   Google Scholar
• Glass O, Henao R, Patel K, et al. Serum interleukin-8, osteopontin, and monocyte chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2018;2:1344–1355.
   PubMed Web of Science ®Google Scholar
• Chen Y, Siegel F, Kipschull S, et al. MiR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. Nat Commun. 2013;4.
   Web of Science ®Google Scholar
• Hartmann P, Tacke F. Tiny RNA with great effects: miR-155 in alcoholic liver disease. J Hepatol. 2016;64:1214–1216.
   PubMed Web of Science ®Google Scholar
• Csak T, Bala S, Lippai D, et al. MicroRNA-155 deficiency attenuates liver steatosis and fibrosis without reducing inflammation in a mouse model of steatohepatitis. PLoS One. 2015;10(6).
   Web of Science ®Google Scholar
• Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332(6037):1519–1523.
   PubMedGoogle Scholar
• Donners MMPC, Wolfs IMJ, Stöger LJ, et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One. 2012;7(4).
   Web of Science ®Google Scholar
• Zhu J, Chen T, Yang L, et al. Regulation of MicroRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One. 2012;7(11).
   Web of Science ®Google Scholar
• Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics. Gut. 2016;65:1895–1905.
   PubMed Web of Science ®Google Scholar
• Yoon J-H, Abdelmohsen K, Gorospe M. Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol. 2013;425:3723–3730.
   PubMed Web of Science ®Google Scholar
• Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–1076.
   PubMed Web of Science ®Google Scholar
• Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145–166.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yan I, Haga H, et al. Long noncoding RNA in liver diseases. Hepatology. 2014;60:744–753.
   PubMed Web of Science ®Google Scholar
• Huang R, Duan X, Fan J, et al. Role of noncoding RNA in development of nonalcoholic fatty liver disease. BioMed Res Int. 2019;2019.
   Web of Science ®Google Scholar
• Hanson A, Wilhelmsen D, DiStefano JK. The role of long non-coding RNAs (lncRNAs) in the development and progression of fibrosis associated with nonalcoholic fatty liver disease (NAFLD). Noncoding RNA. 2018;4:18.
   Google Scholar
• Zhao X-Y, Xiong X, Liu T, et al. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis. Nat Commun. 2018;9:2986.
   PubMed Web of Science ®Google Scholar
• Wang J, Yang W, Chen Z, et al. Long noncoding RNA lncSHGL recruits hnRNPA1 to suppress hepatic gluconeogenesis and lipogenesis. Diabetes. 2018;67:581–593.
   PubMed Web of Science ®Google Scholar
• Negishi M, Wongpalee SP, Sarkar S, et al. A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins. PLoS One. 2014;9(4).
   Web of Science ®Google Scholar
• Bian E-B, Wang -Y-Y, Yang Y, et al. Hotair facilitates hepatic stellate cells activation and fibrogenesis in the liver. Biochim Biophys Acta - Mol Basis Dis. 2017;1863:674–686.
   PubMed Web of Science ®Google Scholar
• Yu F, Jiang Z, Chen B, et al. NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and kruppel-like factor 6. J Mol Med. 2017;95:1191–1202.
   PubMed Web of Science ®Google Scholar
• Shen X, Guo H, Xu J, et al. Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol. 2019;234(10):18169-18179.
   Web of Science ®Google Scholar
• Zhang M, Chi X, Qu N, et al. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis. Biochem Biophys Res Commun. 2018;499:66–70.
   PubMed Web of Science ®Google Scholar
• Chen G, Yu D, Nian X, et al. LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL). Sci Rep. 2016;6:1–13.
   PubMed Web of Science ®Google Scholar
• Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17:205–211.
   PubMed Web of Science ®Google Scholar
• Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12:381–388.
   PubMed Web of Science ®Google Scholar
• Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. CircRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–66.
   PubMed Web of Science ®Google Scholar
• Xie L, Mao M, Xiong K, et al. Circular RNAs: A novel player in development and disease of the central nervous system. Front Cell Neurosci. 2017;11:1–10.
   PubMed Web of Science ®Google Scholar
• Fan X, Weng X, Zhao Y, et al. Circular RNAs in cardiovascular disease: an overview. BioMed Res Int. 2017;2017.
   Web of Science ®Google Scholar
• Zhao Z, Li X, Jian D, et al. Hsa_circ_0054633 in peripheral blood can be used as a diagnostic biomarker of pre-diabetes and type 2 diabetes mellitus. Acta Diabetol. 2017;54:237–245.
   PubMed Web of Science ®Google Scholar
• Yao T, Chen Q, Fu L, et al. Circular RNAs: biogenesis, properties, roles, and their relationships with liver diseases. Hepatol Res. 2017;47:497–504.
   PubMed Web of Science ®Google Scholar
• Song M, Xia L, Sun M, et al. Circular RNA in liver: health and diseases. Adv Exp Med Biol. 2018;245–257.
   Web of Science ®Google Scholar
• Guo XY, Chen JN, Sun F, et al. CircRNA-0046367 prevents hepatoxicity of lipid peroxidation: an inhibitory role against hepatic steatosis. Oxid Med Cell Longev. 2017;2017.
   Web of Science ®Google Scholar
• Guo X-Y, Sun F, Chen J-N, et al. circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling. World J Gastroenterol. 2018;24:323–337.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yuan B, Wu Z, et al. Microarray profiling of circular RNAs and the potential regulatory role of hsa_circ_0071410 in the activated human hepatic stellate cell induced by irradiation. Gene. 2017;629:35–42.
   PubMed Web of Science ®Google Scholar
• Li P, Shan K, Liu Y, et al. CircScd1 promotes fatty liver disease via the janus kinase 2/signal transducer and activator of transcription 5 pathway. Dig Dis Sci. 2019;64:113–122.
   PubMed Web of Science ®Google Scholar